Breakthrough technology for bladder cancer succeeds in Phase II




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Breakthrough technology for bladder cancer succeeds in Phase II
Released on: October 10, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Vesimune (TMX-101), has completed a Phase IIa proof-of-concept clinical trial for the localised treatment of bladder cancer.
  • Summary
  • Transcript
  • Participants
  • Company
Vesimune (TMX-101), has completed a Phase IIa proof-of-concept clinical trial for the localised treatment of bladder cancer. This is a disease of seriously unmet medical need. Vesimune will be the first new targeted therapy in decades, dedicated to bladder cancer and the first compound to modulate the innate immune system for this indication. The trial has had complete responders with elimination of tumours. Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and infectious diseases. CEO, Johanna Holldack talked to Adrian Dawkes at BIO International 2014 in San Diego about it's success so far and the future prospects for the therapy and the company.
Johanna Holldack, CEO, Telormedix
Johanna Holldack
Telormedix
Telormedix
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. The Company’s lead product, TMX-101, proved to have a good safety profile in humans during the first stage of a Phase I/II clinical trial for the localised treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). TMX-101 is a new formulation of a clinically active small molecule compound with a known and favourable safety profile and a specific immunotherapeutic target. Telormedix has optimized TMX-101 specifically for the localised treatment of bladder cancer, the fifth most prevalent cancer and a disease of unmet medical need. TMX-101 will be the first targeted therapy dedicated to bladder cancer and the first to modulate the innate immune system for this indication. The second product, TMX-202, is a small molecule for the topical treatment of skin and bladder cancers. The Company also has third product called TMX-201, which is being developed for use as a vaccine adjuvant. It is currently undergoing preclinical investigation. Telormedix also has an additional pipeline of programmes for autoimmune diseases, which includes TMX-302. Discovery Capability The Company’s discovery capability, managed under an exclusive licensing agreement with the University of California San Diego, draws on years of experience and the world class research standing of its academic partner. Business Development Telormedix welcomes enquiries from potential partners interested in finding out more about its product pipeline.